Shortwave Life Sciences Plc is a life sciences company focused on the development of therapies for mental health conditions, particularly eating disorders and anorexia nervosa. The company engages in early-stage drug development and manages its operations to build value around clinically relevant intellectual property. It is advancing a proprietary buccal film drug delivery platform designed to enable direct absorption of active pharmaceutical ingredients, aiming to improve pharmacokinetics and patient compliance. Shortwave operates primarily in the pharmaceutical sector and is involved in clinical preparation and data analysis to support future regulatory engagements.